Inflammation in chronic heart failure

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 1002-1016

  Parish, Roy C ^a,b,e   Evans, Jeffery D ^c,d  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c UNIVERSITY OF LOUISIANA   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e ULM College of Pharmacy   (United States)

Author keywords

Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors; Cardiomyopathy; Diuretics; Heart failure; HMG CoA reductase inhibitors; Interleukins

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; METOPROLOL; MILRINONE; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; THALIDOMIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; URIC ACID; VALSARTAN;

ANTINEOPLASTIC ACTIVITY; AUTONOMIC DYSFUNCTION; CANCER IMMUNOTHERAPY; CARDIOMYOPATHY; CONTINUOUS INFUSION; GLUCOSE INTOLERANCE; HEART FAILURE; HEART INDEX; HEART RATE VARIABILITY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MEDLINE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; C-REACTIVE PROTEIN; CHRONIC DISEASE; HEART FAILURE; HEART RATE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; NADPH OXIDASE; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA; URIC ACID;

EID: 48249107383     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K272     Document Type: Review

References (87)

1. Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev 2006;14:108-24.
2. Aronow WS, Ann C, Kronzon I, et al. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 1999;115:867-8.
3. Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy 2006;26(suppl):85S-97S; discussion 98S-101S;quiz 106S-8S.
4. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988;62:60A-6A.
5. Tentolouris C, Tousoulis D, Antoniades C, et al. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol 2004;94:301-5.
6. Wisniacki N, Taylor W, Lye M, Wilding PH. Insulin resistance and inflammatory activation in older patients with systolic and diastolic dysfunction. Heart 2005;91:32-7.
7. Cugno M, Mari D, Meroni PL, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004;126:85-92.
8. Guzzetti S, Mezzetti S, Magatelli R, et al. Linear and non-linear 24 h heart rate variability in chronic heart failure. Auton Neurosci 2000;86:114-9.
9. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure. Circulation 1998;98:1510-6.
10. van der Poll T, Loersy S. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995;3:1-12.
11. Hoffman M. Cytokines. In: Stevens C, ed. Clinical immunology and serology: a laboratory perspective. Philadelphia: FA Davis Company, 2003:80-1.
12. Dinarello C. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457-99.
13. Furutani Y. Molecular studies on interleukin-1 alpha. Eur Cytokine Netw 1994;5:533-8.
14. Castell J, Gomez-Lechon M, David M, et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-50.
15. Pretolani M. Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clin Exp Allergy 1999;19:1164-71.
16. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond) 2003;105:45-50.
17. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82.
18. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
20. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-91.
21. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7.
22. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039-44.
23. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989;86:6753-7.
24. Satoh M, Nakamura M, Tamura G, et al. Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 1997;29:716-24.
25. Muller-Werdan U, Schumann H, Fuchs R, et al. Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol 1997;29:2915-23.
26. Yokoyama T, Vaca L, Rossen R, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
27. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(suppl 2):S9-12.
28. Plomgaard P, Keller P, Keller C, Pedersen BK. TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. J Appl Physiol 2005;98:2019-23.
29. Sabelis LW, Senden PJ, Zonderland ML, et al. Determinants of insulin sensitivity in chronic heart failure. Eur J Heart Fail 2003;5:759-65.
30. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 2004;44:78-81.
31. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory oigan. Proc Nutr Soc 2001;60:329-39.
32. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005;54:2939-45.
33. Gonzalez-Ortiz M, Robles-Cervantes JA, Cardenas-Camarena L, Bustos-Saldana R, Martinez-Abundis E. The effects of surgically removing subcutaneous fat on the metabolic profile and insulin sensitivity in obese women after large-volume liposuction treatment. Horm Metab Res 2002;34:446-9.
34. Stevens C. Historical concepts and introduction to serologic testing. In: Stevens C, ed. Clinical immunology and serology. Philadelphia: FA Davis Company, 2003:2-23.
35. Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006;70: 857-63.
36. Rosen BD, Cushman M, Naisir K, et al. Relationship between C-reactive protein levels and regional left ventricular function in asymptomatic individuals. J Am Coll Cardiol 2007;49:594-600.
37. Zweier J, Kuppusamy P, Lutty G. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. Proc Natl Acad Sci U S A 1988;85:4046-50.
38. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations in vasomotor tone. J Clin Invest 1996;97:1916-23.
39. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-9.
40. Zafari A, Ushio-Fukai M, Akers M, et al. Novel role of NADH/NADPH oxidase-derived hydrogen peroxide in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 1998;32:488-95.
41. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998;329(pt 3):653-7.
42. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 2004;1:1-10.
43. Squadrito G, Cueto R, Splenser A, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000;376:333-7.
44. Rubbo H, Tarpey M, Freeman BA. Nitric oxide and reactive oxygen species in vascular injury. Biochem Soc Symp 1995;61:33-45.
45. Santos CXC, Anjos EI, Augusta O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification by lipid oxidation. Arch Biochem Biophys 1999;372:285-94.
46. Suzuki YJ, Ford GD. Redox regulation of signal transduction in cardiac and smooth muscle. J Mol Cell Cardiol 1999;31:345-53.
47. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
48. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
49. White M, Ducharme A, Ibrahim R, et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond) 2006;110:483-9.
50. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
51. Grassi G, Seravalle G, Cattaneo B, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92:3206-11.
52. Bhatnagar S, Al-Yusuf A, Al-Asfoor A. Abnormal autonomic function in diabetic and nondiabetic patients after first acute myocardial infarction. Chest 1987;92:849-52.
53. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996;17:354-81.
54. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993;88:180-5.
55. Molgaard H, Sorensen KE, Bjerregaard P. Attenuated 24-h heart rate variability in apparently healthy subjects, subsequently suffering sudden cardiac death. Clin Auton Res 1991;1:233-7.
56. Soejima K, Akaishi M, Meguro T, et al. Age-adjusted heart rate variability as an index of the severity and prognosis of heart failure. Jpn Circ J 2000;64:32-8.
57. Aronson D, Mittleman MA, Burger AJ. Interleukin-6 levels are inversely correlated with heart rate variability in patients with decompensated heart failure. J Cardiovasc Electrophysiol 2001;12:294-300.
58. Malave HA, Taylor AA, Nattama J, Deswal A, Mann DL. Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability. Chest 2003;123:716-24.
59. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
60. Gullestad L, Aukrust PA, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7.
61. Anand IS, Latini R, Florea VG, et al. C-Reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428-34.
62. Sola S, Mir MQS, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-7.
63. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
64. Gong K, Zhang Z, Sun X, et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J 2006;151:62-8.
65. Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90:1118-22.
66. Xu B, Makris A, Thornton C, Ogle R, Horvath JS, Hennessy A. Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. J Hypertens 2006;24:915-22.
67. Prandota J. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Ther 2002;9:317-28.
68. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995;7:526-33.
69. Kranzhofer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1623-9.
70. Steffen S, Jun L, Carolin F, et al. Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press 2006;15:116-28.
71. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-21.
72. Sardo MA, Castaldo M, Cinquegrani M, et al. Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-a levels in uncomplicated hypertensive patients. Angiology 2004;55:195-203.
73. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001;104:2716-21.
74. Siragy HM, Awad A, Abadir P, Webb R. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003;144:2229-33.
75. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol 2005;21:344-8.
76. Gullestad L, Ueland T, Brunsvig A, et al. Effect of metoprolol on cytokine levels in chronic heart failure - a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 2001;141:418-21.
77. Cinquegrana G, D'Aniello L, Landi M, et al. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. J Card Fail 2005;11:213-9.
78. Satoh M, Ishikawa Y, Minami Y, Akatsu T, Nakamura M. Eplerenone inhibits tumour necrosis factor α shedding process by tumour necrosis factor α converting enzyme in monocytes from patients with congestive heart failure. Heart 2006;92:979-80.
79. Bendtzen K, Hansen PR, Rieneck K. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003;134:151-8.
80. Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 1999;63:934-40.
81. Conraads VM, Bosmans JM, Schuerwegh AJ, et al. Effect of short-term treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and nonischemic disease. J Heart Lung Transplant 2005;24:1114-7.
82. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
83. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-34.
84. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
85. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220-5.
86. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
87. Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005;112:3408-14.